Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis

Authors

  • Farnam B. Sedeh Department of Dermato-venereology, Zealand University Hospital, Roskilde, Denmark
  • Mattias A.S. Henning Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.
  • Gregor B.E. Jemec Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.
  • Kristina S. Ibler Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.

DOI:

https://doi.org/10.2340/actadv.v102.2075

Keywords:

atopic dermatitis, systemic, biological

Abstract

The aim of this study was to compare the efficacies of systemic treatments with dupilumab, tralokinumab and Janus kinase inhibitors for moderate-to-severe atopic dermatitis. A systematic review following Preferred Reporting Items for Systemic Reviews and Meta-Analyses (PRISMA) guidelines was performed using Medline, EMBASE and Cochrane library. All randomized controlled trials investigating the efficacy of systemic treatments for moderate-to-severe atopic dermatitis in adults were included. Primary outcomes were the proportion of patients with atopic dermatitis achieving 50%, 75%, and 90% improvement in Eczema Area and Severity Index (EASI) score after dupilumab, tralokinumab or Janus kinase inhibitors. Nineteen studies totalling 6,444 patients were included. In monotherapy studies, upadacitinib 30 mg once daily had the numerically highest efficacy regarding EASI-50, EASI-75 and EASI-90. In combination therapy studies with topical corticosteroids, dupilumab 300 mg once every other week had highest efficacy regarding EASI-50, and abrocitinib 200 mg once daily had the highest score regarding EASI-75 and EASI-90. Analysis provided evidence that dupilumab, tralokinumab and Janus kinase inhibitors all had an acceptable efficacy profile and resulted in clinically relevant improvements in EASI score. Furthermore, upadacitinib and abrocitinib seem to have great potential to treat patients with atopic dermatitis. However, further studies are needed to determine the long-term efficacy of Janus kinase inhibitors in adults with moderate-to-severe atopic dermatitis.

Downloads

Download data is not yet available.

References

Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI; ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol 2009; 124: 1251-1258.

https://doi.org/10.1016/j.jaci.2009.10.009

Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol 2013; 132: 1132-1138.

https://doi.org/10.1016/j.jaci.2013.08.031

Williams HC. Atopic dermatitis: the epidemiology, causes and prevention of atopic eczema. Cambridge: Cambridge University Press; 2000.

https://doi.org/10.1017/CBO9780511545771

Garmhausen D, Hagemann T, Bieber T, Dimitriou I, Fimmers R, Diepgen T, et al. Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy 2013; 68: 498-506

https://doi.org/10.1111/all.12112

Napolitano M, Megna M, Patruno C, Gisondi P, Ayala F, Balato N. Adult atopic dermatitis: a review. G Ital Dermatol Venereol 2016; 151: 403-411.

Bieber T. Atopic dermatitis. N Engl J Med 2008; 358: 1483-1494.

https://doi.org/10.1056/NEJMra074081

Katsarou A, Armenaka M. Atopic dermatitis in older patients: particular points. J Eur Acad Dermatol Venereol 2011; 25: 12-8.

https://doi.org/10.1111/j.1468-3083.2010.03737.x

McAleer MA, Flohr C, Irvine AD. Management of difficult and severe eczema in childhood. BMJ 2012; 345: e4770.

https://doi.org/10.1136/bmj.e4770

Flohr C, Irvine AD. Systemic therapies for severe atopic dermatitis in children and adults. J Allergy Clin Immunol 2013; 132: 774-774.

https://doi.org/10.1016/j.jaci.2013.03.016

Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 2014; 71: 327-349.

https://doi.org/10.1016/j.jaad.2014.03.030

Sidbury R, Hanifin JM. Systemic therapy of atopic dermatitis. Clin Exp Dermatol 2000; 25: 559-566.

https://doi.org/10.1046/j.1365-2230.2000.00697.x

Megna M, Napolitano M, Patruno C, Villani A, Balato A, Monfrecola G, et al. Systemic treatment of adult atopic dermatitis: a review. Dermatol Ther (Heidelb) 2017; 7: 1-23.

https://doi.org/10.1007/s13555-016-0170-1

Sanofi-Aventis Groupe. Dupixent. Sanofi-Aventis Groupe, Paris, France, 2017.

Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014; 371: 130-139

https://doi.org/10.1056/NEJMoa1314768

Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al.; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335-2348.

https://doi.org/10.1056/NEJMoa1610020

Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2016; 387: 40-52.

https://doi.org/10.1016/S0140-6736(15)00388-8

Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389: 2287-2303.

https://doi.org/10.1016/S0140-6736(17)31191-1

Tsianakas A, Luger TA, Radin A. Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial. Br J Dermatol 2018; 178: 406-414.

https://doi.org/10.1111/bjd.15905

de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol 2018; 178: 1083-1101.

https://doi.org/10.1111/bjd.16156

Blauvelt A, Simpson EL, Tyring SK, Purcell LA, Shumel B, Petro CD, et al. Dupilumab does not affect correlates of vaccine-induced immunity: a randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol 2019; 80: 158-167.

https://doi.org/10.1016/j.jaad.2018.07.048

Guttman-Yassky E, Bissonnette R, Ungar B, Suárez-Fariñas M, Ardeleanu M, Esaki H, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol 2019; 143: 155-172.

https://doi.org/10.1016/j.jaci.2018.08.022

Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE, et al.; JADE COMPARE Investigators. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med 2021; 384: 1101-1112.

https://doi.org/10.1056/NEJMoa2019380

Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol 2019; 143: 135-141.

https://doi.org/10.1016/j.jaci.2018.05.029

Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, et al.; ECZTRA 3 study investigators. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol 2021; 184: 450-463.

https://doi.org/10.1111/bjd.19573

Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, et al.; ECZTRA 1 and ECZTRA 2 study investigators. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 2021; 184: 437-449.

https://doi.org/10.1111/bjd.19574

Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, et al. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial. JAMA Dermatol 2019; 155: 1371-1379.

https://doi.org/10.1001/jamadermatol.2019.2855

Guttman-Yassky E, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol 2019; 80: 913-921.

https://doi.org/10.1016/j.jaad.2018.01.018

Guttman-Yassky E, Thaçi D, Pangan AL, Hong HC, Papp KA, Reich K, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol 2020; 145: 877-884.

https://doi.org/10.1016/j.jaci.2019.11.025

Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2020; 156: 1333-1343.

https://doi.org/10.1001/jamadermatol.2020.3260

Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020; 183: 242-255.

https://doi.org/10.1111/bjd.18898

Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, Prajapati VH, Lio P, Hu X, Wu T, Liu J, Ladizinski B, Chu AD, Eyerich K. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2021; 157: 1047-1055

https://doi.org/10.1001/jamadermatol.2021.3023

Simpson EL, Forman S, Silverberg JI, Zirwas M, Maverakis E, Han G, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). J Am Acad Dermatol 2021; 85: 62-70.

https://doi.org/10.1016/j.jaad.2021.02.028

Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151: 65-94.

https://doi.org/10.7326/0003-4819-151-4-200908180-00136

Mokkink LB, Prinsen CA, Bouter LM, Vet HC, Terwee CB. The Consensus-based Standards for the selection of health Measurement Instruments (COSMIN) and how to select an outcome measurement instrument. Braz J Phys Ther 2016; 19: 105-113.

https://doi.org/10.1590/bjpt-rbf.2014.0143

Silverberg JI, Thyssen JP, Fahrbach K, Mickle K, Cappelleri JC, Romero W et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol 2021; 35: 1797-1810.

https://doi.org/10.1111/jdv.17351

Drucker AM, Morra DE, Prieto-Merino D, Ellis AG, Yiu ZZN, Rochwerg B, et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA Dermatol 2022; 158: 523-532.

https://doi.org/10.1001/jamadermatol.2022.0455

Nusbaum KB, Fleischer S, Fleischer AB Jr. Efficacy of biologics and oral small molecules for atopic dermatitis: a systematic review and meta-analysis. J Dermatolog Treat 2021; 8: 1-11.

Zhou S, Qi F, Gong Y, Zhang J, Zhu B. Biological therapies for atopic dermatitis: a systematic review. Dermatology 2021; 237: 542-552.

https://doi.org/10.1159/000514535

Li C, Sun X, Zhao K, Meng F, Li L, Mu Z, et al. Efficacy and safety of janus kinase inhibitors for the treatment of atopic dermatitis: a systematic review and meta-analysis. Dermatology 2021; 27: 1-11.

Mueller RB, Hasler C, Popp F, Mattow F, Durmisi M, Souza A, et al. Effectiveness, tolerability, and safety of tofacitinib in rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen and Aarau cohorts. J Clin Med 2019; 8: 1548.

https://doi.org/10.3390/jcm8101548

Ma C, Lee JK, Mitra AR, Teriaky A, Choudhary D, Nguyen TM, et al. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment Pharmacol Ther 2019; 50: 5-23.

https://doi.org/10.1111/apt.15297

Winthrop KL, Park SH, Gul A, Cardiel MH, Gomez-Reino JJ, Tanaka Y, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis 2016; 75: 1133-1138.

https://doi.org/10.1136/annrheumdis-2015-207319

Weinhold KJ, Bukowski JF, Brennan TV, Noveck RJ, Staats JS, Lin L, et al. Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers. Clin Immunol 2018; 191: 10-20.

https://doi.org/10.1016/j.clim.2018.03.002

Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, et al. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol 2014; 54: 1354-1361.

https://doi.org/10.1002/jcph.354

Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologictreated patients with rheumatoid arthritis. Ann Rheum Dis 2016; 75: 1843-1847.

https://doi.org/10.1136/annrheumdis-2016-209131

Winthrop KL, Wouters AG, Choy EH, Soma K, Hodge JA, Nduaka CI, et al. The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial. Arthritis Rheumatol 2017; 69: 1969-1977.

https://doi.org/10.1002/art.40187

Almanzar G, Kienle F, Schmalzing M, Maas A, Tony HP, Prelog M. Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis. Rheumatology 2019; 58: 2051-2060.

https://doi.org/10.1093/rheumatology/kez175

Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 2014; 66: 2675-2684.

https://doi.org/10.1002/art.38745

Singh R, Heron CE, Ghamrawi RI, Strowd LC, Feldman SR. Emerging role of janus kinase inhibitors for the treatment of atopic dermatitis. Immunotargets Ther 2020; 9: 255-272.

https://doi.org/10.2147/ITT.S229667

Silverberg NB. Atopic dermatitis prevention and treatment. Cutis 2017; 100: 192.

https://doi.org/10.1016/S0733-8635(17)30058-X

He H, Guttman-Yassky E. JAK inhibitors for atopic dermatitis: an update. Am J Clin Dermatol 2019; 20: 181-190.

https://doi.org/10.1007/s40257-018-0413-2

Downloads

Additional Files

Published

2022-08-24

How to Cite

Sedeh, F. B., Henning, M. A., Jemec, G. . B., & Ibler, K. S. (2022). Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis. Acta Dermato-Venereologica, 102, adv00764. https://doi.org/10.2340/actadv.v102.2075